Bunick Discusses Dual-Target Biologic at EADV 2025

At the European Academy of Dermatology and Venereology (EADV) Congress 2025 in Paris, France, emerging data highlighted a potential breakthrough in the treatment of moderate to severe atopic dermatitis (AD). Christopher Bunick, MD, PhD, associate professor of dermatology at the Yale School of Medicine and Editor-in-Chief of Dermatology Times, presented findings on a late-breaking abstract evaluating galvokamig, an investigational multi-specific biologic targeting IL-13 and IL-17A/F.

According to Bunick, the therapy addresses unmet needs in patients who fail to achieve adequate disease control with currently available options. “One of the things that we know about atopic dermatitis is that it is not just a Th2-driven disease. It is a heterogeneous disease, and for some patients, IL-17 pathways are important,” he explained. By engaging both IL-13 and IL-17A/F, galvokamig is designed to modulate overlapping inflammatory mechanisms that contribute to chronic skin barrier dysfunction and pruritus.

In his interview with Dermatology Times, Bunick emphasized that this therapeutic approach reflects a broader shift toward more personalized strategies in dermatology. “What excites me about this data is that it highlights the complexity of AD and the fact that one-size-fits-all treatment doesn’t work for every patient,” he noted. This perspective underscores the importance of expanding biologic therapies beyond single-cytokine inhibition.

Preliminary efficacy data presented at EADV 2025 suggested that patients treated with galvokamig experienced significant improvements in disease severity scores, itch reduction, and overall quality of life measures. While long-term safety data remain to be fully established, early indications point toward a favorable tolerability profile.

The implications extend beyond clinical outcomes alone. For clinicians, the development of a multi-specific biologic represents an evolution in therapeutic design — one that aligns with the multifactorial nature of atopic dermatitis. As Bunick summarized, the findings presented at EADV “open the door to treating a subset of AD patients who may not respond optimally to currently approved biologics.”

As the field continues to advance, galvokamig and other emerging therapies may redefine treatment algorithms for atopic dermatitis. With ongoing clinical development, dermatologists may soon have access to an expanded toolkit for managing patients whose disease has historically been challenging to control.